IP Library › Granted Patent US 8,492,330
Granted Patent B2
US 8,492,330 · App. 13/004,964 · Granted Jul 23, 2013

Formulation comprising GLP-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,330
App. No.
13/004,964
Granted
Jul 23, 2013
Kind
B2
Abstract

The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.

Claims (9)

1. A formulation comprising a GLP-1 compound of SEQ ID NO:2 and a delivery agent of the formula

or a pharmaceutically acceptable salts salt thereof.

2. The formulation of claim 1 , wherein the GLP-1 compound is DPP IV resistant.

3. The formulation of claim 1 , wherein the delivery agent is a sodium salt of

4. An oral pharmaceutical composition comprising:

(i) a GLP-1 compound, wherein the GLP-1 compound is a GLP-1 derivative comprising a polypeptide of SEQ ID NO:2; and

(ii) a delivery agent selected from

and pharmaceutically acceptable salts thereof.

5. The oral pharmaceutical composition of claim 4 , wherein the delivery agent is a sodium salt of

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →